ScienceGuardians

ScienceGuardians

Did You Know?

ScienceGuardians hosts publishers too

Tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cells

Authors: Jay F. Dorsey,Akiva Mintz,Xiaobing Tian,Melissa L. Dowling,John P. Plastaras,David T. Dicker,Gary D. Kao,Wafik S. El-Deiry
Publisher: American Association for Cancer Research (AACR)
Publish date: 2009-12-1
ISSN: 1535-7163,1538-8514 DOI: 10.1158/1535-7163.mct-09-0415
View on Publisher's Website
Up
0
Down
::

Concern about Supplementary Figure 1A:

Red boxes: In the Mock column, the SF767-scram-GFP-Luc and SF767-p53kd-GFP-Luc panels look identical.
The description of this figure suggests these are two different cell types: “SF767-scram-GFP-Luc and SF767-p53kd-GFP- Luc cells (1×106 cells/plate) were mock treated or treated with a sequential treatment of paclitaxel (1 €M, 12 hours) then TRAIL (50 ng/ml, additional 12 hours), and then imaged with phase-contrast microscopy.”

 

 

  • You must be logged in to reply to this topic.